Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Societe Anonyme/No Pennies -- Ignore unavailable to you. Want to Upgrade?

To: JEB who wrote (26957)	12/12/1998 2:34:00 PM
From: majaman1978	Read Replies (1) \| Respond to of 119973

Those companies were well funded and had many products in the pipelines. I'm not saying ASTM will not do well, but the stock's you mentioned were all brought public at over 20 bucks a share. I owned AMGN when it dropped back to ten, it subsequently went to 100, same with CHIR. Believe it or not I also owned BGEN at 6 bucks. Never made the big bucks, though, since I was not patient enough. The way you really have to play the bio game is to own an assortment of these stocks, and stay with them thru thick and thin in many cases years and years. Day trading vehicles they usually are not, that's why they are tough to trade and in many cases hold. And another point, if these companies do have a promising product, they will have to dip back into the equity market and sell more and more shares in order to fund their testing. That usually means more dilution somewhere down the road. I also subscribed to Jim McCament's Medical Technology Stock Letter for a few years, he has picked some big winners as well as some big bombs, so it works both ways. Usually you don't get in-between with biotech stocks, they either flourish or fade away into oblivion.